Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 14

of '复发或难治性急性髓系白血病的治疗'

Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H
Br J Haematol. 2006;134(1):58.
In order to validate the European Prognostic Index (EPI) for patients<or=60 years with acute myeloid leukaemia in first relapse, a cohort of 599 such patients, treated between 1980 and 2004 at the MD Anderson Cancer Center, were assessed using this prognostic index. Three risk groups were defined: favourable, 76 patients (13%) [Overall survival (OS), 64% at 1 year, 22% at 5 years]; intermediate, 137 patients (23%) (OS, 38% at 1 year, 12% at 5 years); and poor, 386 patients (64%) (OS, 17% at 1 year 6% at 5 years). The EPI is reproducible and useful.
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, 77230-1402, USA. frankgiles@aol.com